26 results about "Dosing drugs" patented technology

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

A pharmaceutical combination for subcutaneous administration and use thereof are provided. The pharmaceutical combination as described herein for subcutaneous administration includes a hyaluronidase and an antibody-drug conjugate. The antibody-drug conjugate includes a fragment of a bioactive molecule, and the bioactive molecule has moderate toxicity. The pharmaceutical combination can achieve a larger volume and a larger dose of administration, and the side reaction is not enhanced.

This invention discloses a wearable ultrasound delivery device for treating otitis media, comprising a wearable main body with a flexible structure adapted to the shape of the patient's ear canal, and a through-hole central channel; an ultrasound drug delivery device, detachably disposed within the central channel, comprising a drug carrier for carrying the therapeutic drug to be delivered, an ultrasound transducer assembly for providing an ultrasound-guided drug delivery mode, and a handheld controller for adjusting the millimeter-level displacement of the drug carrier into the middle ear cavity; wherein, the ultrasound transducer assembly comprises a flexible substrate and multiple piezoelectric transducer units integrated on the flexible substrate, the multiple piezoelectric transducer units constituting a phased array transducer array. This device solves the technical problems of inaccurate drug delivery, low drug delivery efficiency, inability to adapt to the ear canal structure, and complex operation in the prior art.

The utility model relates to the technical field of gynecological drug delivery structures, and discloses a gynecological drug delivery structure which comprises a drug delivery component and a drug delivery tube arranged at the front end of the drug delivery component, a vaginal dilation component is arranged on one side of the drug delivery component, a heating component is arranged on the outer side of the drug delivery component, a rotating rod is rotated, a pressing plate can be pushed to move, and a sponge body can be extruded. According to the vaginal dilation device, the movable vaginal dilation plate and the fixed vaginal dilation plate are provided with the discharge holes, so that the lubricating liquid is discharged from the discharge holes, the surface of the movable vaginal dilation plate and the surface of the fixed vaginal dilation plate are provided with the lubricating liquid respectively, the lubricating purpose can be achieved, and the discomfort caused when the movable vaginal dilation plate and the fixed vaginal dilation plate are inserted into the private part of a patient can be reduced; the threaded rod can be driven to rotate, the movable vaginal dilation plate can be driven by the sliding base to move, the movable vaginal dilation plate can be far away from the fixed vaginal dilation plate, the private part of a patient can be dilated, the push rod can push the piston to move by pressing the handle, and liquid medicine can be discharged from the medicine feeding pipe.

Provided is use of a compound represented by Formula (I), or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I) in the manufacture of a medicament for treating and / or preventing an immune system disease.

The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising dosing a human subject with L-asparaginase.

Some embodiments of the present invention include compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) of the present invention that inhibit IRAK and / or FLT3 and can be used, for example, to treat certain diseases. Some embodiments include administration and methods of using compounds of the present invention (e.g., in compositions or pharmaceutical compositions) to treat (e.g., diseases such as hematopoietic cancer, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatments using a combination of an IRAK and / or FLT3 inhibitor compound of the present invention and another therapy, such as a cancer therapy.

The invention relates to the technical field of injection pumps, and discloses a micro-injection pump integrating automatic bar code recognition and voice control dosing functions, the micro-injection pump comprises a shell and a voice receiving module, the voice receiving module is fixedly arranged at the top end of the shell, the shell comprises a single-layer shell, a control panel is fixedly arranged on the single-layer shell, and a voice control module is fixedly arranged on the control panel. An injection bin body is fixedly arranged at the front end of the single-layer shell, a bin door is detachably arranged on the injection bin body, when the injection bin body and the bin door are closed, the injection bin body and the bin door are in a hollow cylinder shape, and a medicine feeding push block moving left and right is arranged on the single-layer shell. And an information identification assembly, a light extrusion cylinder body positioning assembly and a split driving assembly are arranged in the injection bin body. The invention particularly provides a micro-injection pump integrating automatic bar code recognition and voice control dosing functions. The micro-injection pump is provided with an information recognition assembly, a radio module and a light extrusion cylinder body positioning assembly.

The invention concerns improvements in needle-free devices for delivery of therapeutic and / or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free device disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and / or patient.

Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.

The invention concerns improvements in needle-free devices for the delivery of therapeutic and / or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free devices disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and / or patient.

This invention provides an atomization module for an atomizer, comprising a pressure-resistant solution chamber, a pressure assembly, a heating assembly, and a sealing nozzle. The pressure assembly is connected to the pressure-resistant solution chamber and can increase the pressure inside the chamber. The sealing nozzle is connected to an outlet on the pressure-resistant solution chamber and includes a transition section and a spray plate. The spray plate has an internally closed blind hole. The transition section, the blind hole, and the outlet are interconnected. The blind hole opens from the inside out after exceeding the pressure limit, and the liquid to be atomized is sprayed out from the blind hole. The inner diameters of the pressure-resistant solution chamber, the transition section, and the blind hole decrease sequentially. The heating assembly can heat the pressure-resistant solution chamber. The atomization module of this invention has a faster atomization rate, a larger capacity range for atomized solution per spray, and no special requirements on the device posture during atomization. It can deliver both micro-dose and large-dose drugs as needed, making it more widely applicable.

The invention discloses a sitagliptin phosphate pharmaceutical composition as well as a preparation, a preparation method and application thereof. The pharmaceutical composition comprises sitagliptin phosphate, HP-beta-CD and mesoporous silica. According to the invention, a synergistic effect is generated by utilizing a molecular-level clathration effect of HP-beta-CD and a nano-level confinement adsorption effect of mesoporous silica, so that chemical degradation of sitagliptin phosphate, especially generation of a genotoxic impurity NTTP, is remarkably inhibited from molecular and physical double levels, and the stability of a product is greatly improved. Meanwhile, the mesoporous silica effectively solves the technical problems that HP-beta-CD is strong in hygroscopicity and not easy to directly tablet, and the content uniformity of low-dose drugs is fundamentally ensured by forming uniform composite particles. The process is simple, granulation is not needed, the tablet is suitable for industrial production, the prepared tablet is excellent in stability and high in safety, and animal experiments show that the bioavailability of the tablet is superior to that of a commercially available reference preparation.

The invention discloses preparation of a mesoporous drug-loading system with a controllable aperture and application of the mesoporous drug-loading system in improvement of oral absorption of insoluble drugs, and belongs to the technical field of medicines. The drug loading system takes dendritic mesoporous silica as a carrier of an insoluble drug and fenofibrate as a model drug, is used for improving the physical stability and oral bioavailability of the insoluble drug, and is particularly suitable for clinical large-dose drugs. The dendritic mesoporous silica drug-loading system provided by the invention is superior to commercially available mesoporous auxiliary materials and traditional solid dispersion carrier materials in the aspects of improving the physical stability of the insoluble drug and enhancing the oral absorption effect, and provides important reference for the research of an oral preparation of the insoluble drug.

The invention concerns improvements in needle-free devices for delivery of therapeutic and / or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free device disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and / or patient.

Provided herein are methods of dosing engineered islet cells that include functional modified beta cell containing one or more modifications, such as genetic modifications. In some embodiments, the engineered islets are hypoimmunogenic cells. In some embodiments, the one or more modifications reduce or eliminate expression of one or more MHC class I and / or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).

This invention relates to a transdermal therapeutic system (TTS) for the administration of the active ingredient rotigotine and its preparation method. The transdermal therapeutic system (TTS) comprises a matrix layer containing: rotigotine; one or more non-amine-resistant silicone adhesives in an amount greater than 50% by weight, based on the total weight of the pressure-sensitive adhesives in the matrix layer; and paraffin. The transdermal therapeutic system according to the invention is particularly suitable for the treatment of Parkinson's disease.

The present disclosure describes intranasal knockout bolus formulations, methods, and devices. Olfactory delivery of a therapeutic agent via an intranasal bolus of the therapeutic agent may be reduced or terminated by precision delivery of a knockout bolus of a purging formulation. The knockout bolus may be delivered at a velocity sufficient to physically displace the therapeutic agent from an olfactory cleft, may dilute the intranasal bolus of a therapeutic formulation, or may cause an osmotic pressure sufficient to reverse a direction of a drug flow through a tissue of the olfactory cleft. An ability to modulate or stop delivery of the therapeutic agent via the olfactory cleft allows for more precision dosing and more control of dose timing in response to biometric monitoring.

The present application relates to the technical field of medical equipment, and discloses a gradient expansion coronary expansion balloon and a use method, which comprises a main balloon body, the side surface of the main balloon body is respectively provided with a front end auxiliary balloon body and a rear end auxiliary balloon body along the axial direction thereof, the front end auxiliary balloon body is used for forming support for the normal blood vessel at the distal end of the lesion segment, and the rear end auxiliary balloon body is used for forming support for the normal blood vessel at the proximal end of the lesion segment, so as to realize gradient support in cooperation with the main balloon body, and a multi-cavity delivery catheter extending along the axial direction of the main balloon body is arranged on the main balloon body. The present application can form gradient support for the blood vessel at the lesion segment and the proximal end and the distal end of the lesion segment, avoids the rapid elastic retraction of the blood vessel wall to the lesion segment after the balloon is deflated, increases the effective surface area of the drug carrying, realizes the precise local delivery of high-dose drugs, and can independently adjust the inflation pressure of the main balloon body, the front end auxiliary balloon body and the rear end auxiliary balloon body.

We have identified panels of proxy single nucleotide polymorphisms (SNPs) that are highly predictive of particular HLA risk alleles, and concordant across multi-ethnic populations. Accordingly, methods are provided involving clinical DNA testing for HLA panel markers to assess risk for life-threatening adverse drug reactions associated with the human leucocyte antigen (HLA) alleles HLA-B*57:01, HLA-B*15:02, HLA-A*31:01 and HLA-B*58:01. Methods of treating a subject with a drug associated with an adverse drug reaction (ADR) are provided. Based on the assessed risk to a subject for developing an adverse drug reaction in response to a drug, appropriate administrations of the drug can be made. In some embodiments of the method, the drug is administered when there is a low assessed risk of ADR in the subject. Alternatively, when there is a high assessed risk of ADR in the subject, a reduced dosage of the drug, or no drug, can be administered.

The embodiment of the invention provides an injector for injecting medicine with adjustable dosage, and belongs to the technical field of medical instruments. The trigger mechanism comprises a button and a knob which are clamped together; the adjusting mechanism comprises gear sets meshed together, one end of the adjusting mechanism is fixed to the injector shell and rotatably connected with the triggering mechanism, the other end of the adjusting mechanism is fixedly connected with the adjusting rod, and a torsional spring is arranged in the adjusting mechanism; the push mechanism comprises a push rod and a push part; one end of the push rod is fixedly connected with the button; the other end of the push rod is meshed with the gear set; one end of the push part is fixedly connected with the adjusting rod; the knob is rotated to drive the adjusting rod to rotate to a preset dosage position, and meanwhile the gear set rotates in an engaged mode to enable the torsional spring to store force. The button is pressed to drive the push rod to axially move towards the injection end, so that the gear set is separated, and the torsion spring force release adjusting rod rotates to push the pushing part to push quantitative medicine to complete injection. The injector can adjust and lock the dosage and then automatically inject.

A medical fluid injection device, a medical fluid transfer device and a method of administering and transferring a medical fluid are disclosed. The device and method may include a compressed gas canister in fluid communication with an expandable elastic bladder positioned within a vial of drug to provide a means to deliver drug through an injection cannula that is movable between a plurality of positions or through a transfer conduit.

Provided herein are methods of dosing engineered islet cells that include functional modified beta cell containing one or more modifications, such as genetic modifications. In some embodiments, the engineered islets are hypoimmunogenic cells. In some embodiments, the one or more modifications reduce or eliminate expression of one or more MHC class I and / or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).

This utility model discloses a water treatment dosing device, including a base, an aeration pump on one side of the inner wall of the base, and an air supply pipe connected to the air outlet of the aeration pump. A drive motor is located on one side of the inner wall of the base, and a dosing tank is located at the center of the top of the base. An air injection pipe is located at the bottom of the inner wall of the dosing tank. One end of the air supply pipe is mounted on the top of the air injection pipe via a bearing, and the bottom end of the air injection pipe is fixedly connected to the output end of the drive motor via a flat key. Multiple stirring rods are welded to the outside of the air injection pipe, and multiple air holes are opened on the outside of the air injection pipe. When mixing aqueous solution and chemicals, the aeration pump is started, and the aeration pump injects air into the air injection pipe through the air supply pipe. The air is discharged through the air holes on the air injection pipe. The forced airflow will disturb the chemical particles, achieving full dispersion of the chemical particles. For active ingredients with poor solubility or easy separation, it can significantly improve the uniformity of low-dose drugs and reduce the risk of clumping of hygroscopic drugs due to uneven humidity.